SALT LAKE CITY, Utah (March 26, 2013) — BioFire Diagnostics, Inc. today announced that it has signed a competitive prototyping contract with the Department of the Army for Increment 1 of the Next ...

BioFire Diagnostics Inc. has raised $25 million in new funding from New York-based Athyrium Opportunities Fund. The money will be used to help commercialize the company’s “FilmArray” diagnostic ...

SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray ...

BioFire Diagnostics won 510(k) clearance for its gastrointestinal panel for infectious diarrhea, following in the footsteps of the company's acquisition by French diagnostic giant bioMérieux.

BioMérieux's BioFire Diagnostics got an FDA OK for its rapid meningitis and encephalitis test, a feather in the company's cap as it diversifies its portfolio and ramps up business in an increasingly ...

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary ...

SAN DIEGO, October 01, 2024--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its ...

Diagnostics company bioMerieux has reached an agreement to acquire molecular biology company BioFire Diagnostics for $450 million in a move intended to strengthen the French company’s position in ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Dublin, Nov. 19, 2020 (GLOBE NEWSWIRE) -- The "Global POC Molecular Diagnostics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The publisher has been monitoring the POC ...

Back in 2018, the disgraced biotech company Theranos sold its patent portfolio to Fortress Investment Group, a division of Softbank. Now two of those patents have wound up in the hands of a ...